The revision of the EU Regulations on medicines for children and for rare diseases
Virtual Policy Dialogue WATCH THE DISCUSSION
20 May 2021
12:00-13:30 CEST
online
The revision of the EU legislation on medicines for rare diseases and for children is one of the key actions of the Pharmaceutical Strategy for Europe. Our joint policy dialogue organised with the European Society for Paediatric Oncology, European Fair Pricing Network and the Association of European Cancer Leagues discussed concrete recommendations to deliver optimal treatment for children and those suffering from rare diseases, as ”one-size-fits-all” incentives do not lead to a sustainable and equitable pharmaceutical system.
On Social Media
Our #policy dialogue on the Regulations on #medicines for #kids & #rarediseases is a go! https://t.co/3YOXZ8pNFV
— European Cancer Leagues (@CancerLeagues) May 20, 2021
💊
💊 💊
💊 💊
💊 #LetsTalkAccess 💊
💊 💊
💊 💊
💊 pic.twitter.com/PizdCZNx4C
Pharma, academia, patients and parents, regulatory agencies: let’s work together! To provide access to new medicines for children with cancer by our @SIOPEurope Guru Gilles Vassal #letstalkaccess
— Reineke (@ReinekeSchoot) May 20, 2021
💊The #EU is revising the rules for the development of #medicines & want your opinion!
— European Cancer Leagues (@CancerLeagues) May 20, 2021
Kaja invites you to #EUHaveYourSay by the 3⃣0⃣ July 2021⤵https://t.co/UZs1ZZEuW9#EUPharmaStrategy pic.twitter.com/PhTljqD0Nc
To the needs of patients with orphan diseases we should involve patients and physicians in the research agenda and we need more studies. We should set up a European research and technical infrastructure for easy to conduct and less costly randomised trials. #LetsTalkAccess
— IQWiG (@iqwig) May 20, 2021
👉@olga_kv, @SIOPEurope’s #Policy Director, invite you all to check out & make use of our Joint Recommendations!
— European Cancer Leagues (@CancerLeagues) May 20, 2021
🔎https://t.co/WhFYU3LXRU#LetsTalkAccess #EUPharmaStrategy pic.twitter.com/uXwCJnN9cY
